{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:50:05Z","timestamp":1773211805020,"version":"3.50.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.biopha.2017.07.023","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T16:49:28Z","timestamp":1500655768000},"page":"1277-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Managing metastatic bone pain: New perspectives, different solutions"],"prefix":"10.1016","volume":"93","author":[{"given":"Iwona","family":"Zaporowska-Stachowiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"\u0141uczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Stachowiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wies\u0142aw","family":"Bryl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Sopata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2017.07.023_bib0005","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0015","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ar.21150","article-title":"Computed microtomography of bone specimens for rapid analysis of bone changes associated with malignancy","volume":"293","author":"Chappard","year":"2010","journal-title":"Anat. Rec."},{"key":"10.1016\/j.biopha.2017.07.023_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2009.01.011","article-title":"Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors","volume":"283","author":"Fili","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2017.07.023_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00432-002-0350-5","article-title":"A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma","volume":"128","author":"Stokkel","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra030831","article-title":"Mechanism of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.07.023_bib0035","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.biopha.2017.07.023_bib0040","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","article-title":"Histopathological assessment of prostate cancer bone osteoblastic metastases","volume":"180","author":"Roudier","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0045","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/1097-0142(19830301)51:5<918::AID-CNCR2820510526>3.0.CO;2-J","article-title":"Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia","volume":"51","author":"Charhon","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.pcan.4500607","article-title":"The potential role of bisphosphonates in prostate cancer","volume":"5","author":"Oades","year":"2002","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.biopha.2017.07.023_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0305-7372(06)80007-1","article-title":"Conclusion Bone markers in metastatic bone disease","volume":"32","author":"Coleman","year":"2006","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0093-7754(01)90260-X","article-title":"The role of zolendronic acid in cancer: clinical studies in the treatment and prevention of bone metastases","volume":"28","author":"Coleman","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/A:1015599831232","article-title":"Prostate carcinoma skeletal metastases: crosstalk between tumor and bone","volume":"20","author":"Keller","year":"2001","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2010.227","article-title":"Bone metastasis: mechanism of therapeutic opportunities","volume":"7","author":"Suva","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0075","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/clinchem\/41.10.1489","article-title":"Biochemical markers of bone turnover in patients with metastatic bone disease","volume":"41","author":"Demers","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.biopha.2017.07.023_bib0080","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/path.2684","article-title":"Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis","volume":"221","author":"Baud\u2019huin","year":"2010","journal-title":"J. Pathol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0090","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to RANCe\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2017.07.023_bib0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2017.07.023_bib0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0105","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","article-title":"Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells","volume":"100","author":"Mancino","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0115","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ijc.20056","article-title":"Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte\/macrophage colony-stimulating factor","volume":"109","author":"Morgan","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CBC.2005.s.004","article-title":"Molecular mechanism of breast cancer metastases to bone","volume":"5","author":"Guise","year":"2005","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0125","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","article-title":"Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis","volume":"98","author":"Guise","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2017.07.023_bib0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-\u03b2 signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2017.07.023_bib0135","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI0217124","article-title":"Manipulating the environment of cancer cells in bone: a novel therapeutic approach","volume":"110","author":"Martin","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2017.07.023_bib0140","first-page":"3059","article-title":"Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites","volume":"51","author":"Powell","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0145","first-page":"2631","article-title":"Osteoblast-related transcription factors Runx2 (Cbfa1\/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells","volume":"63","author":"Barnes","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0150","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.critrevonc.2013.08.013","article-title":"Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers","volume":"89","author":"Kruger","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0155","doi-asserted-by":"crossref","first-page":"16666","DOI":"10.1074\/jbc.M001123200","article-title":"Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack","volume":"275","author":"Fedarko","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2017.07.023_bib0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","article-title":"Activin A circulating levels in patients with bone metastasis from breast or prostate cancer","volume":"23","author":"Leto","year":"2006","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.biopha.2017.07.023_bib0165","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.07.023_bib0170","first-page":"18","volume":"19","author":"Guise","year":"1998","journal-title":"Cancer Bone Endocr. Rev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0175","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1158\/1078-0432.CCR-06-0813","article-title":"Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis","volume":"12","author":"Vessella","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0180","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0006-291X(90)90886-R","article-title":"Production and significance of TGF-beta in AT-3 metastatic cell line established from Dunning rat prostatic adenocarcinoma","volume":"166","author":"Matuo","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2017.07.023_bib0185","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jcb.20735","article-title":"Role of Wnts in prostate cancer bone metastases","volume":"97","author":"Hall","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.biopha.2017.07.023_bib0190","first-page":"917","article-title":"Tumor-derived platalet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer","volume":"62","author":"Yi","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2017.07.023_bib0195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/er.2006-0001","article-title":"The role of the IGF system in cancer growth and metastasis: overview and recent insights","volume":"28","author":"Samani","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0200","first-page":"2587","article-title":"Prostate cancer cells-osteoblast interaction shifts expression of growth\/survival-related genes in prostat\u0119 cancer and reduces expression of osteoprotegerin in osteoblasts","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2017.07.023_bib0205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/pros.21277","article-title":"DOCKKOPF-1 (DKK-1) stimulated prostate cancer growth and metastasiss and inhibited bone formation in osteoblastic bone metastases","volume":"71","author":"Nanda","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.biopha.2017.07.023_bib0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00345-004-0478-9","article-title":"Endothelin receptor antagonists","volume":"23","author":"Nelson","year":"2005","journal-title":"World J. Urol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0215","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/jn\/125.suppl_7.2028S","article-title":"Endothelin receptors, second messengers, and actions in bone","volume":"125","author":"Stern","year":"1995","journal-title":"J. Nutr."},{"issue":"6","key":"10.1016\/j.biopha.2017.07.023_bib0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.phrs.2011.01.002","article-title":"Endothelins and their receptors in cancer: identification of therapeutic targets","volume":"63","author":"Wang","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0225","doi-asserted-by":"crossref","first-page":"10921","DOI":"10.1158\/0008-5472.CAN-05-1809","article-title":"Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity","volume":"65","author":"Kitagawa","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0230","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/en.2005-1502","article-title":"Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8","volume":"147","author":"Valta","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2017.07.023_bib0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/ar2169","article-title":"Tumor metastasis to bone","volume":"9","author":"Virk","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2017.07.023_bib0240","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nm.1979","article-title":"TGF-\u03b21-induced migration of bone mesenchymal cells couples bone resorption with formation","volume":"15","author":"Tang","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2017.07.023_bib0245","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(17)66278-5","article-title":"Calcium studies in ten cases of osteoblastic prostatic metastasis","volume":"79","author":"Roland","year":"1958","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0250","first-page":"6326","article-title":"Detection and clinical implications of early systemic tumor cell dissemination in breast cancer","volume":"9","author":"Pantel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0255","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zolendronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0260","doi-asserted-by":"crossref","first-page":"5396","DOI":"10.1158\/1078-0432.CCR-04-2420","article-title":"Angiogenesis in the bone marrow of patients with breast cancer","volume":"11","author":"Chavez-Macgregor","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0265","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","article-title":"Clinical course and prognostic factors following recurrence from breast cancer","volume":"77","author":"Coleman","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0270","series-title":"Tumor Bone Disease and Osteoporosis in Cancer Patients","first-page":"457","article-title":"Bisphosphonates in the treatment of multiple myeloma","author":"Kanis","year":"2000"},{"key":"10.1016\/j.biopha.2017.07.023_bib0275","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5489\/cuaj.117","article-title":"Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice","volume":"6","author":"So","year":"2012","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.biopha.2017.07.023_bib0280","series-title":"Chory na nowotw\u00f3r. Kompendium leczenia b\u00f3lu","first-page":"399","article-title":"B\u00f3l kostny","author":"Filipczak-Bryniarska","year":"2013"},{"key":"10.1016\/j.biopha.2017.07.023_bib0285","first-page":"121","article-title":"Bone and cancer: the osteoncology","volume":"10","author":"Ibrahim","year":"2013","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"10.1016\/j.biopha.2017.07.023_bib0290","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00066-002-0928-5","article-title":"Systemic mast cell disease (SMCD) and bone pain. A case treated with radiotherapy","volume":"178","author":"Hesselmann","year":"2002","journal-title":"Strahlenther. Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0295","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0022-3476(05)80535-9","article-title":"Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes","volume":"117","author":"Johnson","year":"1990","journal-title":"J. Pediatr."},{"key":"10.1016\/j.biopha.2017.07.023_bib0300","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/apmr.2002.32308","article-title":"Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report","volume":"83","author":"Lin","year":"2002","journal-title":"Arch. Phys. Med. Rehab."},{"key":"10.1016\/j.biopha.2017.07.023_bib0305","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10585-012-9530-0","article-title":"A micro-imaging study linking bone cancer pain with tumor growth and bone resorption in a rat model","volume":"30","author":"Dor\u00e9-Savard","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.biopha.2017.07.023_bib0310","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jpainsymman.2005.01.008","article-title":"Bone cancer pain: from model to mechanism to therapy","volume":"29","author":"Luger","year":"2005","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2017.07.023_bib0315","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/978-3-642-82028-1_7","article-title":"Frequency of pain in patients with cancer","volume":"89","author":"Wagner","year":"1984","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1191\/0269216304pm890oa","article-title":"Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey","volume":"18","author":"Caraceni","year":"2004","journal-title":"Palliat. Med."},{"key":"10.1016\/j.biopha.2017.07.023_bib0325","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/0973-1075.92333","article-title":"Pain in blood cancers","volume":"17","author":"Niscola","year":"2011","journal-title":"Indian J. Palliat. Care"},{"key":"10.1016\/j.biopha.2017.07.023_bib0330","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0304-3959(99)00073-1","article-title":"An international survey of cancer pain characteristics and syndromes, IASP Task Force on Cancer Pain, International Association for the Study of Pain","volume":"82","author":"Caraceni","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2017.07.023_bib0335","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0340","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jpainsymman.2005.04.002","article-title":"Predictors of quality of life in oncology outpatients with pain from bone metastasis","volume":"20","author":"Rusteon","year":"2005","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.biopha.2017.07.023_bib0345","series-title":"Cancer Pain Relief","author":"World Health Organization","year":"1996"},{"key":"10.1016\/j.biopha.2017.07.023_bib0350","doi-asserted-by":"crossref","first-page":"44131","DOI":"10.18632\/oncotarget.17311","article-title":"Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy","volume":"8","author":"Wenter","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2017.07.023_bib0355","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1158\/1078-0432.CCR-10-0600","article-title":"Novel bone-targeted strategies in oncology","volume":"16","author":"Vallet","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0360","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2009.04.022","article-title":"A djuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?","volume":"45","author":"Coleman","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0365","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.07.023_bib0370","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0375","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0380","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0305-7372(02)00095-6","article-title":"The anti-tumour activity of bisphosphonates","volume":"28","author":"Neville-Webbe","year":"2002","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0385","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2007.10.067","article-title":"The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells","volume":"580","author":"Valenti","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0390","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0395","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0400","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0405","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0410","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma","volume":"84","author":"Vij","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2017.07.023_bib0415","doi-asserted-by":"crossref","DOI":"10.1186\/s13569-016-0056-0","article-title":"Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone","volume":"6","author":"Gaston","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0420","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Mundy","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2017.07.023_bib0425","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"97","key":"10.1016\/j.biopha.2017.07.023_bib0430","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007 a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"1","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.07.023_bib0435","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and RANK:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0440","first-page":"807","article-title":"Local in vivo administration of a decoy oligonucleotide targeting NF-kappaB induces apoptosis of osteoclasts after application of orthodontic forces to rat teeth","volume":"18","author":"Penolazzi","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2017.07.023_bib0445","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2017.07.023_bib0450","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood.V112.11.2739.2739","article-title":"Promoting osteoblastogenesis using a novel Dkk-1 neutralizing antibody in the treatment of multiple myeloma related bone disease","volume":"112","author":"Pozzi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2017.07.023_bib0455","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/1078-0432.CCR-05-2074","article-title":"A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases","volume":"12","author":"Lara","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2017.07.023_bib0460","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/gut.46.5.670","article-title":"Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease","volume":"46","author":"di Mola","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2017.07.023_bib0465","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.neuro.29.051605.112929","article-title":"Neurotrophins: mediators and modulators of pain","volume":"29","author":"Pezet","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2017.07.023_bib0470","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1523\/JNEUROSCI.3300-10.2010","article-title":"Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain","volume":"30","author":"Jimenez-Andrade","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2017.07.023_bib0475","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/j.pain.0000000000000211","article-title":"Efficacy and safety of tanezumab in the treatment of pain from bone metastases","volume":"156","author":"Sopata","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2017.07.023_bib0480","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1093\/emboj\/cdg294","article-title":"GAP43 stimulates inositol triphosphate-mediated calcium release in response to hypotonicity","volume":"22","author":"Caprini","year":"2003","journal-title":"EMBO J."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217316554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217316554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:13:42Z","timestamp":1766024022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217316554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":96,"alternative-id":["S0753332217316554"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.07.023","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing metastatic bone pain: New perspectives, different solutions","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}